NORTHVALE, NJ / ACCESSWIRE / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced the first shipment of generic Adderall XR to its distribution and marketing partner Prasco, LLC ("Prasco"). Adderall XR is an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules (the "Products").
Prasco is, pursuant to the manufacturing and supply agreement dated April 5, 2023 ("Agreement") between the companies, a non-exclusive U.S. distributor of the Products. Prasco will market the Products under Burel Pharmaceutical's label, and Elite will manufacture the Products. Elite's product is co-owned with Mikah Pharma.
About Prasco, LLC
Prasco is a privately held healthcare company located in Mason, Ohio. Over 50 of the most innovative and trusted pharmaceutical companies have relied on Prasco to bring their products to the US generic marketplace. Prasco provides patients with high-quality products at affordable prices in over 60,000 US pharmacies. For more information, visit the company's website at .
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit .
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
SOURCE: Elite Pharmaceuticals, Inc.
View the original press release on accesswire.com
新泽西州诺斯维尔/ACCESSWIRE/2023年12月12日/开发利基仿制药的专业制药公司Elite Pharmicals, Inc.(“精英” 或 “公司”)(OTCQB: ELTP)今天宣布向其分销和营销合作伙伴Prasco, LLC(“Prasco”)首次发货仿制药Adderall XR。Adderall XR 是单体苯丙胺产品(糖精右旋苯丙胺、天冬氨酸、硫酸右旋苯丙胺、硫酸苯丙胺)的缓释混合盐,其浓度为 5 mg、10 mg、15 mg、20 mg、25 mg 和 30 mg 胶囊(“产品”)。
根据两家公司于2023年4月5日签订的制造和供应协议(“协议”),Prasco是产品的非独家美国分销商。Prasco将以Burel Pharmaceutical的标签销售这些产品,而Elite将生产这些产品。Elite的产品与Mikah Pharma共同拥有。
关于 Prasco, LLC
Prasco是一家私人控股的医疗保健公司,位于俄亥俄州梅森。50多家最具创新性和最值得信赖的制药公司都依靠Prasco将其产品推向美国仿制药市场。Prasco 在美国超过 60,000 家药店以实惠的价格为患者提供高质量的产品。欲了解更多信息,请访问该公司的网站,网址为。
关于精英制药有限公司
Elite Pharmicals, Inc. 是一家开发、制造和分销利基仿制药的专业制药公司。Elite的产品线包括速释和控释固体口服剂量产品,这些产品以Elite Laboratories的标签销售,并根据授予第三方药品营销和分销组织的许可证进行销售。Elite在新泽西州诺斯维尔经营一家经cGMP和DEA注册的研究、开发和制造工厂。欲了解更多信息,请访问。
本新闻稿包含1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”,包括但不限于与对未来业绩、业绩或其他预期的影响(如果有)相关的陈述,这些影响可能与本新闻稿的主题有一定关系。请读者注意,此类前瞻性陈述涉及但不限于Elite无法控制的风险、不确定性和其他因素,这些因素可能导致Elite的实际业绩、业绩或成就与这些前瞻性陈述可能暗示的业绩、业绩或其他预期存在重大差异。这些前瞻性陈述可能包括有关FDA批准产品的预期时间(如果有的话)的陈述,以及FDA为获得此类批准可能要求Elite采取的行动。这些前瞻性陈述并不能保证未来的行动或业绩。Elite向美国证券交易委员会提交的文件中不受限制地讨论了这些风险和其他因素,包括其10-K、10-Q和8-K表的报告。无论是由于新信息、未来事件还是其他原因,Elite没有义务更新或修改其前瞻性陈述。
联系人:
适用于精英制药公司
戴安娜·威尔,投资者关系,518-398-6222
Dianne@elitepharma.com
来源:精英制药公司
在 accesswire.com 上查看原始新闻稿